For research use only. Not for therapeutic Use.
CTCE-0214 is a chemokine CXC receptor 4 (CXCR4) agonist, SDF-1α (stromal cell-derived factor-1α) peptide analog. CTCE-0214 shows anti-inflammatory activity, and can be used in inflammation sepsis and systemic inflammatory syndromes research[1][2][3].
CTCE-0214 (0.01-0.1 ng/mL; 4 d) increases the expansion of CD34+ cells subsets[3].
CTCE-0214 (intravenous injection; 1-25 mg/kg; once) treatment inhibits Lipopolysaccharide-induced plasma TNF-α production[1].
CTCE-0214 (intraperitoneal injection and intravenous injection; 25 mg/kg; once) decreases Zymosan-induced plasma TNF-α production[1].
| Catalog Number | I042539 |
| CAS Number | 577782-52-6 |
| Molecular Formula | C170H254N44O40 |
| Purity | ≥95% |
| Reference | [1]. Fan H, et al. Beneficial effect of a CXCR4 agonist in murine models of systemic inflammation. Inflammation. 2012 Feb;35(1):130-7. [2]. Faber A, et al. The many facets of SDF-1alpha, CXCR4 agonists and antagonists on hematopoietic progenitor cells. J Biomed Biotechnol. 2007;2007(3):26065. [3]. Li K, et al. Small peptide analogue of SDF-1alpha supports survival of cord blood CD34+ cells in synergy with other cytokines and enhances their ex vivo expansion and engraftment into nonobese diabetic/severe combined immunodeficient mice. Stem Cells. 2006 Jan;24(1):55-64. |
